Last reviewed · How we verify
KH607 tablet
At a glance
| Generic name | KH607 tablet |
|---|---|
| Sponsor | Chengdu Kanghong Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder (PHASE2)
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression (PHASE2)
- Phase 1 Study of KH607 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KH607 tablet CI brief — competitive landscape report
- KH607 tablet updates RSS · CI watch RSS
- Chengdu Kanghong Pharmaceutical Group Co., Ltd. portfolio CI